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A B S T R A C T   
Background: Blinding is considered an important methodological characteristic in clinical trials to minimise bias 
and maximise the validity of a trial. Unlike pharmaceutical substances, most herbal medicines have distinctive 
sensory specifications, including odour and taste, which can be quite challenging when developing a placebo 
control to match the specific characteristics of herbal substances being examined. The present study was, 
therefore, designed to evaluate whether the participants could differentiate an active herbal capsule (Ganopoly 
combination) from a placebo material capsule. The aim of this study was to develop a suitable placebo substance 
for encapsulation to be used in a future herbal medicine clinical trial. 
Methods: The current study was improved upon the previous investigation, and several modifications were made 
to the placebo substance in order to mimic the herbal substance characteristics. Prior to conducting the study, a 
refined placebo substance was developed using commonly consumed culinary agents. Sixty-two healthy vol-
unteers participated in the study and were randomly provided one of the two substances. Individuals were asked 
to evaluate the three sensory characteristics of the allocated capsule (visual appearance, odour, and taste), and 
determine whether they believed the substance to be a ‘herbal’ or a ‘placebo’ substance. 
Results: The study provided evidence on the success of blinding for only two sensory characteristics, namely, 
visual appearance (95% CI -0.15, 0.34) and odour (95% CI -0.34, 0.15). In contrast, the findings related to the 
taste indicated that participants correctly guessed the herbal substance compared to the placebo substance to a 
significantly higher proportion than would have been expected by chance alone (95% CI 0.14, 0.60). 
Conclusion: The failure to blind participants for taste highlights the difficulties in preparing placebo herbal 
substances that match as closely as possible to a real herbal substance. Blinding is particularly challenging where 
herbal medicines have different sensory characteristics.   
1. Introduction 
Herbal medicines have become an essential part of healthcare 
globally [1,2]. Many clinicians and researchers believe traditional 
herbal medicine will play an increasing role in global health [3]. Among 
different herbal products, Chinese herbal medicine (CHM) is popular 
around the world although its effectiveness remains contentious [4]. 
Over the last several decades, the scientific evidence, including both 
experimental and clinical, has demonstrated the efficacy of some CHM 
for a range of illnesses and conditions [5]. Randomised controlled 
clinical trials (RCTs) are widely acknowledged as the criterion standard 
for unbiased assessment of the effect of the pharmacologic treatments 
[6]. In this regard, blinding is recognized as an important design feature, 
and the cornerstone of a rigorous evaluation in such trials [6,7]. Due to 
the importance of the blinding success, the CONSORT statement has 
incorporated this feature as one of 22 items (11a-b) when investigators 
report their RCTs [8]. However, it is unclear what constitutes adequate 
evidence of blinding success [9]. Furthermore, the quality of the choice 
of control interventions within published trials has been repeatedly 
criticized [2,4,7,10]. Poor development and selection of control treat-
ments is deemed to affect the success of blinding as well as the efficacy of 
the administered interventions [4,11]. High-quality RCTs are, therefore, 
required to further enhance and support acceptance of CHM [10]. 
Despite the importance of blinding, reporting of this critical feature 
is infrequent and often inadequately described in published studies 
[11–13]. In this respect, Hopton and MacPherson stated that the quality 
of a trial cannot be established unless the blinding is evaluated [14]. 
Others, however remain unconvinced that all trialists should conduct a 
blinding assessment exercise [15]. Nevertheless, blinding is widely 
acknowledged as an important methodological feature in RCTs [11,13, 
16], and should be integrated into the study design whenever possible 
[13]. Methods of assessing and reporting the success of blinding, 
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however, is a controversial issue [16], and may be difficult to achieve in 
some situations [11,17]. While the magnitude of blinding is ascertained 
by directly asking participants and other associates at several stages 
during or at the end of a trial [11], evaluating the success of blinding is 
suggested to be more reliable when determined before the evaluation of 
the clinical trial outcome [15]. In a pre-trial assessment of blinding 
study, Walter and colleagues explained that “A pre-trial assessment can 
be based on establishing if one can reliably distinguish between the two 
types of medication, using some form of head-to-head comparison of 
their physical or other characteristics” [13]. 
Currently, research on herbal medicines poses various challenges 
including issues related to the ethical concerns, quality control, study 
design and more specifically, the selection of a control (placebo, usual 
care, or some form of an active intervention) [1]. The Council for In-
ternational Organizations of Medical Sciences have defined placebo as 
“an inert substance or sham procedure is provided to research partici-
pants with the aim of making it impossible for them, and usually the 
researchers themselves, to know who is receiving an active or inactive 
intervention” [18]. However, other research team have argued that a 
placebo cannot be defined in any logical way and, therefore, there is no 
commonly accepted definition of placebo [19,20]. 
Unlike pharmaceutical substances, most Chinese herbs have 
distinctive sensory characteristics which makes blinding very difficult. 
For instance, selecting a matching control in certain herbal products 
which contain ginger is a challenging task due to the unique odour of the 
herb [1]. To overcome this problem, researchers often encapsulate the 
herbal substance and the placebo substance. In our previous study, two 
experiments were undertaken to determine whether a credible placebo 
substance could be developed for use in a clinical trial for CHM. The 
study highlighted the difficulties involved in preparing placebo herbal 
substances that look, smell and taste as similar as possible to the real 
herbal substance [21]. 
The current study was, therefore, designed to determine whether a 
participant could identify a herbal capsule or a placebo capsule when 
randomised to receive one or the other. This study was also improved by 
modifying the taste and colour of the placebo substance used in our 
previous published study [21] to be as similar as possible to the herbal 
substance. It is noted that while this study did not involve a comparison 
comparable to the real-life situation of a clinical trial, the outcome of the 
current study will assist the development of suitable placebo substance 
for encapsulation which may eventually be used in a future clinical trial. 
2. Materials and methods 
2.1. Study overview 
The study involved two substances, a refined placebo substance and 
a herbal substance. Participants were randomly provided one of the two 
substances and asked, using a questionnaire whether they believed the 
substance to be a ‘herbal’ or a ‘placebo’ substance. While the partici-
pants were blind to their capsule allocation (either herbal or placebo) no 
eye pad was necessary as there was no comparison with other substances 
which was the case in the previous published study. 
2.2. Setting and participants 
All data were collected on site at the University of Technology Syd-
ney (UTS). Ethics approval was obtained from the UTS Human Research 
Ethics Committee (UTS HREC 2009–070) prior to commencing the 
study. Participants were sought from the local university environment 
and included undergraduate students. All participants were given an 
information sheet and asked to sign a consent form prior to participating 
in the study. 
Sixty-two healthy participants, who were not taking any medication, 
were recruited by word of mouth, as the method involved the sample 
being drawn from a population that is “close at hand”, that is readily 
available and convenient [22]. Participants were excluded if they had 
any food sensitivities or known food allergies. 
2.3. Herbal substance 
The herbal substance, Ganopoly combination, is derived from 
extracted material of two active ingredients, Ganoderma Lucidum (so- 
called Lingzhi mushroom) [23] and Cordyceps Sinensis (Dong Chong Xia 
Cao) which literally means ‘winter worm-summer grass’ [24]. The 
herbal supplement is currently manufactured by Alpha Bio-Tech Aust 
Pty Ltd (QLD, Australia) and is listed in the Australian Register of 
Therapeutic Goods (ARTG) with the following listed number-L71644. 
The capsule contained 500 mg of G. Lucidum (equivalent to dry 20 g) 
and 100 mg of C. Sinensis (equivalent to dry 200 mg) [25]. 
Both ingredients have a long history of use for a variety of health 
conditions [19,21]. Ganoderma Lucidum, a medicinal mushroom, has 
been used for promoting health and longevity in Asian countries [23, 
26]. The G. Lucidum, medicinal mushroom, is purportedly considered 
beneficial for a broad range of conditions having a number of biological 
activities [27], and its growing popularity is reported to be due to its 
polysaccharides which have both anti-tumour and hypoglycemic activ-
ities [26]. In terms of taste, G. Lucidum is reported as bitter due to the 
high levels of triterpenes [28]. However, the triterpenes concentration is 
varied in the different parts and growing stage of the mushroom [29,30]. 
It should be noted that although it is a common practice to apply the 
originally European name ‘Ganoderma lucidum’ to G. Lucidum and G. 
Lingzhi fungi, the approach has been questioned by several taxonomists. 
In 2016, a research team investigated basidiocarp morphology and 
phylogenetic analyses of the two fungi and concluded that basidiocarp 
of Ganoderma lucidum is identified as G. lucidum s. str. whereas basi-
diocarp of Ganoderma Lingzhi represents G. Lingzhi. Further analysis 
also showed a higher diversity and higher amounts of ganoderic acids in 
G. lingzhi than in G. lucidum that probably are responsible for the bitter 
taste of the ethanol extract of the latter [31]. 
The other extract Cordyceps Sinesis, medicinal fungi, also has a long- 
standing use in China and other Asian countries for a variety of condi-
tions, including treatment of infectious diseases [32]. Several bioactive 
constituents have been extracted from C. Sinesis such as cordycepin, 
polysaccharides, ergosterol, mannitol, and adenosine [33,34] with a 
wide range of pharmacological actions (e.g., nephroprotective, hep-
atoprotective, and inflammatory effects) [33]. Evidence from an vitro 
study indicated that C. Sinesis is an activator of innate immune re-
sponses that activates macrophages by engaging Toll-like receptors and 
inducing mitogen-activated protein kinase pathways characteristic of 
inflammatory stimuli [32]. C. Sinensis is described as sweet in taste and 
neutral in nature according to the theory of Chinese medicine [35,36]. 
2.4. Placebo substances 
Prior to conducting the current study, a refined substance was 
developed based on the materials used for the placebo substance in our 
previous study [21]. While the placebo substances were required to have 
a strong flavour similar to that of the herbal substance, it also needed to 
be as therapeutically inert as possible. It should be highlighted that it is 
extremely difficult to have a substance that is physiologically inert once 
ingested, commonly used culinary agents that are frequently ingested in 
daily life were selected for the current study. The ingredients for the 
placebo material was comprised of (a) ground unprocessed (brown) rice; 
(b) food colouring agents (Queen brand) of yellow, red, and blue with a 
ratio of 6:9:6; (c) a mixture of black pepper (McKenzie’s Ground Black 
pepper), curry powder (Masters of Spices brand) and ground rice with a 
ratio of 3:4:12 (Fig. 1). 
It should be noted that the placebo materials used in the current 
study were modified and improved in three ways compared with the 
earlier published study [21]. First, ground rice was used instead of 
cornflour to give a grainier texture to the base material based on several 
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participants comments in the earlier published study that there was a 
difference between the cornflour based material and the real herbal 
substance. Second, a darker colouring agent was used to colour the 
placebo materials giving them a similar colour to the herbal substance. 
Lastly, the flavouring agents of black pepper and curry powder were 
used together in the placebo material to provide a more complex taste. 
2.5. Study design and data collection procedures 
The current study aimed to evaluate whether the participants could 
differentiate an active herbal capsule from a placebo material capsule. 
This design of the study regarding the intervention administration was 
different to the previous study in that during a two arm (active versus 
control placebo) clinical trial, a participant is only allocated to one 
treatment, either the herbal capsule or the placebo control capsule, 
unless of course, it is a cross over design. Participants were randomised 
using a permuted block of four participants and an envelope as the 
method of randomization to balance numbers for each type of capsule to 
receive either capsule A (placebo) or capsule B (herbal substance). To 
randomise the sequence of testing, 31 envelopes had the word placebo 
inside, and the remaining 31 had the word herbal. Each participant was 
asked to select one envelope from a block of four randomly chosen en-
velopes, and the participant was given the material that was indicted 
inside the envelope they had selected (A denoted placebo while B 
denoted herbal). 
A simple self-designed questionnaire was developed and adminis-
tered to all participants during the study. The questionnaire was con-
sisted of three questions to evaluate the success of blinding with respect 
to visual appearance, smell and taste. Individuals were required to 
choose one of three response categories for each of the question and 
decide whether the allocated capsule was a ‘herbal substance’, a ‘pla-
cebo substance’. The questionnaire also included a descriptor item, 
‘don’t know’ (DK), for participants if they were indecisive concerning 
the capsule provided. The method used in the study is the most prevalent 
method for obtaining the data needed for blinding assessment [37] and 
has been used in different studies [37–39]. Participants also needed to 
identify if they had previously ingested herbal medicine and methods of 
delivery (i.e. pill, granules, and decoction). In addition, an identical 
open-ended question was used for examination of the individual ques-
tions for the sensory characteristics (n = 3) to capture participants re-
sponses for the selected response choices. This assists in identifying what 
cues may have been important for the participants in discriminating the 
placebo from the herbal substance. 
The materials were packed in transparent capsules (00 size) which 
were sealed by bringing the two halves of the capsule together (Fig. 2). 
The capsules were then placed in transparent plastic bottles. 
The procedure for evaluating the capsule involved first asking each 
participant to visually examine the capsule, then smell the unopened 
capsule and then finally to break the capsule and taste with a wet 
fingertip the substance inside the capsule. Participants were required to 
complete the questionnaire only on one occasion. 
3. Statistical analysis 
To establish statistical power, it was estimated that a sample size of 
62 participants would be required for this preliminary study considering 
potential drop-out or withdrawal cases. This was based on the condition 
that to test the null hypothesis, the proportion correctly choosing the 
herbal is 0.5 (i.e. indistinguishable from chance) versus the alternative 
hypothesis, and that the proportion was 0.7, given a power of 0.9. 
Statistical analyses comprised of both descriptive statistics and a 
two-proportion hypothesis (z-test for the difference of proportions) to 
determine whether a statistically significant difference existed between 
the binomial proportions of the allocated groups. A sub-analysis (chi- 
square test for association) was also conducted to investigate if there was 
an association between the pre-experience of herbal medicine intake and 
participants’ choice of responses. In a case where the expected cell 
counts identified below five, Fisher’s Exact test was reported. Data 
analysis was performed using the statistical program, IBM SPSS Statistics 
Software (Version 26, USA). The null hypothesis (H0) was set to test the 
observed number of correct guesses for each capsule, group A or group B 
at random, with a probability of 1/2 for each group due to a 1 in 2 
chance. Under H0, a similar percentage of individuals in each group 
should perceive that the substance they are observing, smelling and 
tasting was a herbal substance or a placebo substance with a two-tailed 
probability parameter equal to 0.5. 
4. Results 
A total of 62 healthy volunteers fulfilled the inclusion criteria and 
participated in the study with a mean age of 40.3 ± 14.1 years (range 
15–68 years). Among participants, forty-one were females (66%) with 
an average age of 40.68 ± 13.78 (range 17–67 years), while twenty-one 
were males (33.9%) with an average age of 39.52 ± 14.97 (range 15–68 
years). The homogeneity of age range was also evaluated by gender 
(male cf female). The results indicated that homogeneity of variances 
was met as assessed by Levene’s test for equality of variances (p =
0.995). There was not a statistically significant difference in the age 
range between male and female participants in the study, t (60) =
− 0.305, p = 0.762. 
Among participants, females (n = 40; 97.6%) reported greater 
experience in previously ingested herbal medicine compared to male 
participants (n = 17; 81%) (Table 1). 
Of the 62 participants who reported previously taking herbal medi-
cine in the study, 41.93% had used all three forms of herbal medicine, 
including pills, decoction, and granules (PGD). The remaining 
Fig. 1. Visual appearance of materials used (powder form); Note. A = placebo 
substance; B= Herbal substance. 
Fig. 2. Visual appearance of materials used (encapsulated form); Note. A =
Placebo substance; B= Herbal substance. 
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participants used other combinations, as shown in Fig. 3. 
In the current study, the proportion of correct and incorrect re-
sponses were statistically compared and ‘DK responses were excluded 
for further analysis given that DK respondents were genuinely uncertain 
about the status of their assigned capsule. One research team stated that 
most reports excluded data on participants answering DK from the sta-
tistical analysis [16]. Regarding this perspective, another research team 
stated that DK responses may be indicative of disagreement and, 
therefore, could be considered as a more favourable result since in-
dicates a high magnitude of blinding [11]. It is worthwhile noting that in 
all the three examinations, correct guesses are least supportive of the 
blinding. 
The results for visual appearance using a two-proportion hypothesis 
test showed that a similar proportion of participants (20 cf 17) believed 
they were receiving an herbal substance (p = 0.435) (Table 2). 
A similar result was also obtained for odour, implying that the pla-
cebo substance was successful in blinding an equal proportion of par-
ticipants (p = 0.443), those that received the herbal material and those 
that received the placebo material (13 cf 16) (Table 3). 
In contrast, the results related to the taste implied that participants 
correctly judged the herbal substance versus placebo substance to a 
greater proportion than would have been expected by chance alone. 
Indeed, a statistically more significant proportion of participants in the 
herbal group believed they were tasting an herbal substance (p = 0.002) 
compared to the placebo substance (22 cf 10) (Table 4). 
Participants were also asked to provide reasons for their choices 
concerning individual examinations. In most cases, no reasons were 
given (NRG) for each of the three examinations, visual appearance (12 
out of 54), odour (10 out of 53), and taste (8 out of 52). A list of reasons 
for the individual type of responses were also thematically investigated, 
and the most frequent rational for the participants’ choices were 
captured. Regarding the visual appearance of the capsules, ‘herbal look’ 
was the most frequent reasons identified by the participants (n = 6); 
however, five out of six incorrectly differentiated the capsules. Colour 
was the second most frequently reported reason (n = 4), where only two 
participants correctly identified herbal substances with an equal number 
of participants for DK and incorrect guess (n = 1). A similar pattern was 
also observed when participants assessed the odour of the capsules. 
Although ‘herbal smell’ was the most rational reason, in most cases, 
participants were incorrectly differentiating the capsule (8 out of 9). 
In contrast, for the taste question, ‘herbal taste’ was the most iden-
tified reason. Indeed, three out of six respondents correctly identified the 
capsule with one respondent selecting the DK response. ‘Pepper taste’ 
was the second most rationale for participants choice and correctly 
guessed in most cases (4 out of 5) followed by ‘bitter taste’ (4 out of 4) 
(Fig. 4). 
A further investigation was also conducted to explore the rationale 
for participants’ selection of DK responses for the three sensory char-
acteristics in both assignments. In most instances, participants did not 
provide any explicit reasons for the selection of the DK category. Indeed, 
participants’ reasoning were predominantly synonymous which was 
interpreted as ‘unable to identify’ with the following ratios for individ-
ual characteristics; visual appearance (10 out of 15; 66.6%), smell (6 out 
of 8; 75%), and teste (2 out of 6; 33.3%). 
Additionally, the results from Fisher’s Exact test indicated no sta-
tistically significant association between the pre-experience of herbal 
medicine intake and participants’ choice of responses (p = 0.056). 
5. Discussion 
The importance of blinding in clinical trials has been repeatedly 
highlighted by regulatory and advisory agencies such as FDA [40] to 
prevent potential sources of bias [17,41] in RCTs. Yet, blinding in 
clinical research on herbal medicine poses various challenges [1]. 
Several factors including colour, odour and taste of the herbs must be 
standardised prior to commencing a study to ensure that the substances 
being evaluated in both the active and control group are comparable and 
Table 1 
Participants’ previous experience of herbal medicine by gender.   
Gender, n (%) 
Female Male 
Taken herbs previously 40 (97.6) 17 (81.0) 
Never taken herbs previously 1 (2.4) 4 (19.0) 
Total valid participants (n = 62). 
Fig. 3. Types of herbal delivery modes previously ingested among participants; 
NA = no answer; PGD = pills, decoction, granules; PG = pills, granules; PD =
pills, decoction. 
Table 2 
Frequency of participants guesses by group assignment for visual appearance.   
Participants guesses, n (%) 
Assignment Correct Incorrect Don’t know 
Capsule B (Herbal substance) 20 (64.5) 3 (9.7) 8 (25.8) 
Capsule A (Placebo substance) 5 (16.1) 17 (54.8) 9 (29.0)  
Z = 0.78; p = 0.435 
95% CI [-0.15, 0.34]  
Total valid participants (n=62), with an equal number in each assignment 
(n=31). 
Table 3 
Frequency of participants guesses by group assignment for odour.   
Participants guesses, n (%) 
Assignment Correct Incorrect Don’t know 
Capsule B (Herbal substance) 13 (41.9) 13 (41.9) 5 (16.1) 
Capsule A (Placebo substance) 11 (35.5) 16 (51.6) 4 (12.9)  
Z = − 0.77; p = 0.443 
95% CI [-0.34, 0.15]  
Total valid participants (n = 62), with an equal number in each assignment (n =
31). 
Table 4 
Frequency of participants guesses by group assignment for taste.   
Participants guesses, n (%) 
Assignment Correct Incorrect Don’t know 
Capsule B (Herbal substance) 22 (71.0) 7 (22.6) 2 (6.4) 
Capsule A (Placebo substance) 15 (50.0) 10 (33.3) 5 (16.7)  
Z = 3.17; p = 0.002 
95% CI [0.14, 0.60]  
Total valid participants (n = 61), number in Capsule B (n = 31) and Capsule A (n 
= 30); missing case (n = 1) in Capsule A. 
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have similar characteristics [1,17]. However, it is sometimes difficult or 
not feasible to design a flawlessly matched control [4] substance for 
some modalities of complementary medicine [19,42]. Another potential 
challenge is at what point in time during a trial, should participants be 
asked for their group allocation perception (i.e. asking before and/or 
during the early stage and/or at the end of the treatment phase) [42]. 
Currently, methods of assessing and reporting the success of blinding 
are contentious with no clear existing guidelines for adequately 
reporting the success of blinding [16]. Boutron et al. in a review of 
blinding in RCTs confirmed that the success of blinding is rarely 
described in reports [16]. In our previous research, a series of studies 
were developed aiming to identify important cues and features that may 
threaten participant blinding in an herbal medicine trial [21]. Similar to 
our previous study, a specific assessment approach was followed, 
including a visual appearance assessment, odour and taste evaluation. 
The current study attempted to improve upon the previous investiga-
tion, and therefore, several modifications were made to the placebo 
substance in order to mimic the herbal substance, as close as possible, in 
terms of texture, colour, and the flavour. The results of the current study 
indicated successful blinding for both visual and odour examinations as 
statistically similar proportions of participants believed they received 
herbal substances. However, this was not the case for the taste since a 
statistically greater proportion of participants correctly selected the 
herbal substance than the comparator substance. Additionally, the study 
findings indicated that previous experience of herbal medicine intake 
did not influence participants’ choice of responses. However, the results 
should be interpreted with cautions due to small sample size. 
One possible reason for unsuccessful blinding regarding taste could 
be that a sizeable proportion of participants had previous experience 
with ingesting herbal substances and had used all three forms of herbal 
medicine, including pills, decoction, and granules at some point in their 
lives. One may suggest recruiting participants who are herbal medicine 
naïve for future studies, although that is not the case in real practice. 
Herbal medicines are individualistic in approach [1], and often huge 
variations exist (i.e. source, preparation, dose and indication) in the way 
in which the medicines are used in herbal medicine practice. Hence, to 
generalize the results from a structured and highly monitored trial to 
what will happen in the real world practice of the herbal medicine may 
be complicated [3]. In RCTs, the choice of a placebo control group is not 
simple [43] and the level of blinding of a trial [9] depends on the nature 
of the study. In addition, whether or not a substance is inert to some 
extent depends on the condition being evaluated (e.g. using a sugar pill 
for a patient in a trial for diabetes) [44]. 
It is also worth noting that while successful development of a control 
group (e.g., placebo substance) in a formal setting may assist others in 
the development of valid study design, this may not serve as an exact 
reference for future clinical trials. Matching placebo control substances 
cannot simply be purchased in an ‘off-the-shelf’ manner and its provi-
sion needs to be specific to each trial and the challenge is in the task of 
‘matching’ [45]. In the current study, clear capsules were used for both 
assignments where participants could visually observe the substances in 
sealed capsules. Opaque or coated capsules are suggested in future 
herbal medicine trials to blind practitioners and practitioners from 
identifying which capsules contain the active medication or comparator 
product. However, this must conform to several regulations, one of 
which is a specific blinding feature that requires capsules to resists 
tampering and clearly reveal when tampering has occurred [46]. 
Nevertheless, it should be highlighted that research in herbal medi-
cine must attempt to achieve a balance between internal validity (i.e. 
rigor) and external validity (i.e. generalizability) [3,43]. 
Other likely explanations for correctly guessing the herbal capsule 
are as follows: (1) participants were able to differentiate ‘pepper taste’ in 
the placebo substance; (2) participants expected the herbal substance to 
be bitter which could be partly explained due to higher dosage of G. 
Lucidum in each capsule. Similar to our previous study [21], the findings 
highlight that although not all herbal substances taste bitter, partici-
pants may expect the herbal substance to be bitter. It should be noted 
that differences in cultivation in different geographical locations under 
different climatic conditions and the natural genetic development (e.g., 
mutation, recombination) may affect the properties (i.e. taste) of indi-
vidual species [28]. It is, therefore, an important factor to keep in mind 
when preparing and selecting placebo substances for future clinical 
Fig. 4. Comparison of the most frequent rational for participants’ choices (correct, incorrect, don’t know) for the three examination (visual, odour, taste) regardless 
of participant allocation. NRG = no reason given. 
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studies of herbal medicine. 
5.1. Limitation and suggestion for future research 
There are several limitations to this study that need to be acknowl-
edged. Unlike pharmaceutical substances, CHM have special macro-
scopic, and sensory features including appearance, colour, odour and 
taste based on the origin of the constituents [47]. Hence, one major 
challenge was to develop a truly inert material with no, minimal or 
specific physiological effects and yet be identical to the characteristics of 
a herbal substance. Additionally, as discussed in our previous paper 
[21], culinary spices such as curry powder [48] and black pepper [49] 
which were used to develop the placebo substance in the current study 
have been reported to have some potential therapeutic value. However, 
this is always difficult as no substance, is truly physiologically inert once 
ingested [21]. Despite this, in order to improve blinding outcome, we 
suggest that placebo substances need to have a bitter taste, yet, smell as 
similar as possible to the real herbal substance being tested and smell 
less of culinary spices. Where possible, inert flavouring and colouring 
agents should also be used to avoid any undesirable therapeutic effect. 
Furthermore, optional ancillary data could have been additionally 
collected from participants who declined to venture an opinion (i.e. 
don’t know) by additionally requesting them to choose a capsule any-
way in order to validate the responses. However, the major drawback 
associated with this approach is that participants would have been the 
coercive nature of the request. 
6. Conclusion 
A series of studies were undertaken to evaluate the success of 
blinding. The current study highlights the challenges involved in 
blinding participants in herbal RCTs. Despite all the attempts to blind 
participants concerning the examinations of all three sensory charac-
teristics, the sense of taste remains difficult to blind. A potential problem 
for any herbal clinical trial would be that participants may break a 
capsule and taste the substances. Herbal medicines may exhibit a strong 
aroma or a distinguished taste which can be problematic when devel-
oping a control. Additionally, the relevance of blinding may vary based 
on the clinical trial context. While it may be unavoidable to use sub-
stances that have a physiological effect, every effort should be made to 
ensure that the placebo substance does not have an specific identifiable 
physiological effect on the condition being evaluated. 
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[20] A. Hróbjartsson, What are the main methodological problems in the estimation of 
placebo effects? J. Clin. Epidemiol. 55 (5) (2002) 430–435. 
[21] B. Loyeung, et al., An experimental study in distinguishing an authentic herbal 
substance from sham herbal substances, Compl. Ther. Med. 39 (2018) 92–96. 
[22] F.J. Fowler, Survey Research Methods, fourth ed., Sage Publications, Thousand 
Oaks, 2009. 
[23] S. Wachtel-Galor, et al., Ganoderma Lucidum (Lingzhi or Reishi): A Medicinal 
Mushroom, in: I.F.F. Benzie, S. Wachtel-Galor (Eds.), Herbal Medicine: 
Biomolecular and Clinical Aspects, Nd, CRC Press/Taylor & Francis Llc, Boca Raton 
(FL, 2011. 
[24] H.-C. Lo, et al., A systematic review of the mysterious caterpillar fungus 
ophiocordyceps sinensis in Dong Chong Xia Cao and related bioactive ingredients, 
Journal of traditional and complementary medicine 3 (1) (2013) 16–32. 
[25] Australian Registry of Therapeutic Goods (ARTG), Ganopoly capsules. 1/10/2020. 
https://search.tga.gov.au/s/search.html?collection=tga-websites-web&que 
ry=71644&op=Search. 
[26] X.-F. Bao, et al., Structural features of immunologically active polysaccharides 
from Ganoderma lucidum, Phytochemistry 59 (2) (2002) 175–181. 
[27] E.K. Li, et al., Safety and efficacy of Ganoderma lucidum (lingzhi) and San Miao 
San supplementation in patients with rheumatoid arthritis: a double-blind, 
randomized, placebo-controlled pilot trial, Arthritis Rheum. 57 (7) (2007) 
1143–1150. 
[28] S. Wachtel-Galor, J. Yuen, J.A. Buswell, Ganoderma Lucidum (Lingzhi or Reishi): A 
Medicinal Mushroom, in: I.F.F. Benzie, S. Wachtel-Galor (Eds.), Herbal Medicine: 
Biomolecular and Clinical Aspects, Taylor and Francis Group, 2011. 
[29] B. Boh, et al., in: M.R. El-Gewely (Ed.), Ganoderma Lucidum and its 
Pharmaceutically Active Compounds, in Biotechnology Annual Review, Elsevier, 
2007, pp. 265–301. 
[30] L. Packer, et al., Herbal and Traditional Medicine: Biomolecular and Clinical 
Aspects, second ed., CRC Press, New York, USA, 2004. 
[31] F. Hennicke, et al., Distinguishing commercially grown Ganoderma lucidum from 
Ganoderma lingzhi from Europe and East Asia on the basis of morphology, 
molecular phylogeny, and triterpenic acid profiles, Phytochemistry 127 (2016) 
29–37. 
[32] J.L. Jordan, A.M. Sullivan, T.D. Lee, Immune activation by a sterile aqueous extract 
of Cordyceps sinensis: mechanism of action, Immunopharmacol. Immunotoxicol. 
30 (1) (2008) 53–70. 
[33] K. Yue, et al., The Genus Cordyceps: a Chemical and Pharmacological Review, 
Wiley Subscription Services, Inc., Bognor Regis, 2013, pp. 474–493. 
[34] Y. Liu, et al., The Chemical Constituents and Pharmacological Actions of Cordyceps 
Sinensis vol. 2015, Evid Based Complement Alternat Med, 2015, 575063. 
[35] B. Lin, S. Li, in: I.F.F. Benzie, S. Wachtel-Galor (Eds.), Cordyceps as an Herbal Drug, 
in Herbal Medicine :Biomolecular and Clinical Aspects, Taylor and Francis Group, 
2011. 
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